Cell growth can be suppressed by stressful environments, but the role of stress pathways in this process is largely unknown. Here we show that a cascade of p38β mitogen-activated protein kinase (MAPK) and p38-regulated/activated kinase (PRAK) plays a role in energy-starvation-induced suppression of mammalian target of rapamycin (mTOR), and that energy starvation activates the p38β-PRAK cascade. Depletion of p38β or PRAK diminishes the suppression of mTOR complex 1 (mTORC1) and reduction of cell size induced by energy starvation. We show that p38β-PRAK operates independently of the known mTORC1 inactivation
The p38 MAPK signalling pathway is evolutionarily conserved from yeast to humans and participates in a variety of cellular responses [1] [2] [3] [4] . There are four mammalian members in the p38 group of MAPK: p38α, p38β, p38γ and p38δ (refs 5-8) . Similarities in activation and function have been observed, but each p38 isoform also has specific functions 9 . Although activation of p38 MAPKs by different stimuli is dependent on cell type, various stress stimuli, including energy stress, activate the p38 pathway in all cells, and thus the p38 pathway is considered to be a major stress-activated signalling pathway 10 . A number of substrates of p38 group MAPKs have been identified, including transcription factors and protein kinases, and the p38 pathway not only regulates gene expression, but also some other cellular responses to stress. mTOR is a highly conserved protein kinase that plays a critical role in controlling cell growth and metabolism [11] [12] [13] . mTOR exists in two distinct complexes called mTORC1 and mTORC2 (ref. 14) . The immunosuppression drug rapamycin inhibits mTORC1 (ref. 15 ), but not mTORC2 (ref. 16 ). The two complexes catalyse phosphorylation of different substrates, and thus execute different functions 17 . mTORC1 integrates signals from growth factors, nutrients, stress and energy levels in regulating cell growth. mTORC2 phosphorylates the hydrophobic motif of AKT (also known as protein kinase B) and modulates cytoskeletal organization 18 . mTORC1 contains regulatory-associated protein of mTOR (Raptor) 19 , mammalian lethal with Sec13 protein 8 (mLST8, also known as GβL; ref. 20) , proline-rich AKT substrate 40 kDa (PRAS40; ref. 21 ) and DEP-domain-containing mTOR interacting protein (Deptor) 22 . AMPK is upstream of mTORC1 in the energy-starvation-induced cellular response 23, 24 . Energy depletion activates AMPK, which phosphorylates TSC2, thereby increasing its GTPase-activation protein (GAP) activity 25 . TSC2 is a GAP for the small G-protein Rheb (ref. 26) , and Rheb is a key regulator of mTORC1 (refs 27,28) . As the GTP-bound form of Rheb activates mTORC1, TSC2 negatively regulates mTORC1 (refs 26,29,30) . Direct phosphorylation of Raptor by AMPK has been reported, and Raptor phosphorylation also negatively regulates the activity of mTORC1 (ref. 31) . The p70 S6 kinase (S6K1) and eIF4E binding protein 1 (4EBP1) are key regulators of translation, and are the most well-characterized targets of mTORC1 (ref. 32) . Phosphorylation of S6K and 4EBP1 by mTORC1 leads to increased translation of specific messenger RNAs, which is part of the mechanism used by mTORC1 to regulate cell growth. Flag-p38β phosphorylation levels and Flag-p38β levels in Flag-immunoprecipitates were determined by western blotting using anti-phospho-p38 and anti-Flag antibodies, respectively. (Note, owing to the similar size of p38 family members, there is no method available at present to specifically detect p38β phosphorylation. Therefore, we used transiently expressed Flag-p38β to determine whether 2-DG can activate p38β. Uncropped images of blots are shown in Supplementary Fig. S9 .
Crosstalk between the p38 and mTOR pathways has been reported. Phosphorylation of Ser 1210 of TSC2 by MK2, a downstream kinase of p38α, creates a 14-3-3 binding site, which prevents TSC2 from inhibiting mTORC1 (ref. 33) . Involvement of the p38 pathway in H 2 O 2 -and other stimuli-induced mTORC1 activation was also reported recently 34 . As both mTOR and p38 pathways are evolutionarily conserved signal pathways, we are interested in their relationship during the cellular response to energy stress, and found that the p38β-PRAK cascade is essential for energy-starvation-induced inactivation of mTORC1.
RESULTS p38β is essential for energy-depletion-induced inhibition of mTORC1
To determine the involvement of the p38 pathway in energydepletion-induced inactivation of mTORC1, we analysed whether knockout of p38α, p38β, p38γ or p38δ could affect 2-deoxy-glucose (2-DG)-induced dephosphorylation of p70 S6K1, an in vitro model for measuring energy-depletion-induced inactivation of mTORC1 (ref. 25 ). 2-DG-induced dephosphorylation of S6K1 in p38α, p38γ and p38δ knockout MEF cells is similar to that in their corresponding p38α +/+ , p38γ +/+ and p38δ +/+ MEF cells, but the dephosphorylation of S6K1 was blocked in p38β −/− MEF cells in comparison with p38β +/+ MEF cells (Fig. 1a) , indicating that p38β is important for S6K1 dephosphorylation. A concentration of 25 mM 2-DG can effectively inhibit the phosphorylation of S6K1, 4EBP1 and S6 in wild-type MEF cells, but not in p38β −/− cells, even at higher 2-DG doses (Fig. 1b) . Dynamic analysis also shows the impaired 2-DG response in p38β −/− cells ( Supplementary Fig. S1a ). The p38β-specific effect on 2-DG-induced dephosphorylation of S6K1 was also observed in HEK293 cells (Supplementary Fig. S1b ). As mTORC1 controls cell size 35, 36 , we analysed the size of wild-type and p38β −/− MEFs before and after 2-DG and rapamycin treatment. Interestingly, 2-DG did not reduce the size of p38β −/− cells as it did in wild-type MEF cells, whereas inhibition of mTORC1 by rapamycin reduced cell size in both cell types (Fig. 1c) . Consistent with the cell size data, rapamycin eliminated phospho-S6K1 in both cells, whereas the effect of 2-DG on phospho-S6K1 was impaired in p38β −/− cells (Fig. 1d) . In support of the role of p38β in 2-DG-induced inactivation of mTORC1, overexpression of p38β, but not other p38 group members, suppressed S6K1 phosphorylation ( Fig. 1e and Supplementary Fig. S1c ), although 2-DG activated not only p38β, but also some other p38 group members ( Fig. 1f and Supplementary Fig. S1d ). 
MEF cells. PRAK
+/+ and PRAK −/− MEF cells were treated with nothing (control), were serum-starved for 36 h, or were treated with 6.25 mM 2-DG or 20 nM rapamycin for 60 h. Cells were collected for FACS analysis to determine cell size. FCS (forward scatter) is a relative measure of cell size. The cell size distribution curve of the control, as indicated by the blue line, is included in each image for comparison purposes. Uncropped images of blots are shown in Supplementary Fig. S9 .
PRAK is essential for energy-depletion-induced inhibition of mTORC1
One means by which the p38 group kinases execute their function is through their downstream kinases. To evaluate the possibility that p38β regulates mTORC1 through activation of its downstream kinases, we analysed whether deletion of PRAK (ref. 37) or MK2 (refs 38, 39) , the kinases that can be activated by p38β (refs 40,41) , affects 2-DG-induced dephosphorylation of S6K1 in MEF cells. Deletion of PRAK, but not MK2, impaired 2-DG-induced dephosphorylation of S6K1 (Fig. 2a) . In support of the role of PRAK in mTORC1 inactivation, reconstitution of PRAK expression in PRAK −/− MEFs restored 2-DG-induced dephosphorylation of S6K1 in PRAK −/− cells (Fig. 2b) , and overexpression of PRAK inhibited S6K1 phosphorylation (Fig. 2c) . Knockdown of PRAK, but not MK2, in HEK293 cells also impaired 2-DG-induced dephosphorylation of S6K1 ( Supplementary  Fig. S2a,b) . 2-DG can activate PRAK, as demonstrated by Thr 182 phosphorylation, and this activation is eliminated by p38β knockout (Fig. 2d) , indicating that the p38β-mediated regulation of mTORC1 activity occurs at least partly through PRAK. As with p38β, PRAK is also required for the 2-DG-induced decrease in cell size and has no role in the serum-deprivation-or rapamycin-induced change in cell size (Fig. 2e) .
p38β-PRAK cascade is selectively involved in certain forms of energy-depletion-induced mTORC1 inactivation
As 2-DG functions through inhibition of glycolysis to cause energy depletion in cells, glucose deprivation in culture medium should induce a similar phenotype. As anticipated, glucose deprivation induced activation of p38β and PRAK, as indicated by the increase in phosphorylation levels of these proteins (Fig. 3a) , and low-glucoseinduced dephosphorylation of S6K1 was impaired in p38β −/− and PRAK −/− cells (Fig. 3b,c death induced by glucose deprivation, and rapamycin treatment was able to rescue this phenotype ( Supplementary Fig. S2c ). AMPK plays a key role in cellular energy homeostasis by sensing changes in the AMP/ATP ratio 42 . Its activity can be determined by phosphorylation of its substrate Raptor. We treated cells with 5-aminoimidazole-4-carboxamide 1-β-d-ribofuranoside (AICAR) and metformin 24 , compounds that can activate AMPK, and found that both can activate p38β and AMPK (Fig. 3a) , but only AICARinduced dephosphorylation of S6K1 was impaired in p38β −/− and PRAK −/− cells ( Fig. 3d-g ). We also examined carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), an uncoupler of oxidative phosphorylation, and found that it activated p38β and AMPK (Fig. 3a) , but its mediated dephosphorylation of S6K1 was not p38β-PRAK dependent (Fig. 3h,i) . It is unclear why p38β-PRAK has no role in metformin-and FCCP-induced inactivation of mTORC1. A recent report showed that the metformin-induced inactivation of mTORC1 is independent of AMPK (ref. 43) , which is consistent with our observation that the mechanism used by metformin to induce mTORC1 inactivation is different from that used by AICAR.
We also tested other stimuli that can affect mTORC1 activity and found that PRAK deletion has little or no effect on the insulininduced phosphorylation of S6K1 ( Supplementary Fig. S3a ), or on the dephosphorylation of S6K1 mediated by the depletion of serum or amino acids ( Supplementary Fig. S3b,c) . Rapamycin-and highosmolarity (sorbitol)-mediated dephosphorylation of S6K1 were also not affected by PRAK knockout (Supplementary Fig. S3c) . Collectively, the p38β-PRAK pathway selectively participates in 2-DG-, AICAR-and glucose-deprivation-induced inactivation of mTORC1.
p38β-PRAK cascade is independent of AMPK and TSC2
The p38β-PRAK cascade should function upstream of mTORC1, because deletion of p38β or PRAK does not affect rapamycin-mediated dephosphorylation of S6K1 and cell-size reduction (Fig. 1c-e mTORC1, we used AMPKα1/α2 double-knockout MEFs. Consistent with published data 31 , 2-DG and AICAR were not able to induce Raptor phosphorylation in AMPK-deficient cells (Fig. 4a) . As 2-DGand AICAR-induced p38β phosphorylation was not affected by AMPK deletion (Fig. 4a) , AMPK is not upstream of p38β activation. Consistently, p38β phosphorylation was also not affected by deletion of TSC2, a downstream target of AMPK (Fig. 4a ). As treatment with AICAR or 2-DG induced similar Thr 172 phosphorylation of AMPK in wild-type and PRAK −/− MEF cells (Fig. 4b,c ), p38β-PRAK should have no role in AMPK activation. The activation of AMPK by AICAR and 2-DG in wild-type and PRAK −/− cells was confirmed by the phosphorylation of the AMPK substrate Raptor (Fig. 4d,e) . Similar data were obtained using p38β −/− cells (Fig. 4f) . Thus, AMPK and p38β-PRAK are parallel pathways.
TSC2 is a suppressor of mTORC1 and acts downstream of AMPK (ref. 25) . It is known that 2-DG-or AICAR-induced dephosphorylation of S6K1 is impaired in TSC2 −/− cells 25 . Both 2-DG and AICAR can downregulate S6K1 phosphorylation in PRAK-overexpressing TSC2 cells, but not in vector-transfected TSC2 −/− cells (Fig. 5a ,b), indicating that overexpressed PRAK can compensate for the loss of TSC2 function in TSC2 −/− cells. As a high dose (2 mM) of AICAR can suppress S6K1 phosphorylation in TSC2 −/− cells 31 , we tested whether PRAK knockdown can make TSC2 −/− cells more resistant to AICAR. TSC2 −/− cells were resistant to low-dose (0.5 mM) AICAR-induced inactivation of mTORC1 and, as anticipated, we were not able to see any effect of PRAK knockdown (Fig. 5c ). We observed that knockdown of PRAK in TSC2 −/− cells enhances the resistance to 2 mM AICAR in these cells (Fig. 5d) , consistent with the conclusion that PRAK is in parallel with TSC2 in regulating mTORC1. In addition, we observed that expression of PRAK further suppresses S6K1 phosphorylation in the presence of overexpressed TSC2 in wild-type cells (Fig. 5e) , and that TSC2-overexpressionmediated inhibition of S6K1 phosphorylation does not require PRAK (Fig. 5f ). Collectively, our data show that TSC2 and PRAK are independent of each other, and can compensate for each other in the inactivation of mTORC1. 
PRAK phosphorylates Rheb at Ser 130 and reduces the ability of Rheb to activate mTORC1
Raptor is a component of mTORC1 and is a target of AMPK in suppressing mTORC1 activity 31 . Neither a knockout cell line nor a dominant-negative mutant of Raptor is available; however, a fusion of Raptor with the carboxy-terminal 20 amino-acid portion of Rheb can create a dominant-active Raptor (Raptor DA ; ref. 44 ; K-L. Guan, unpublished data). Raptor DA expression activated mTOR, as determined by increased phosphorylation of S6K1, and overexpression of wild-type PRAK, but not the kinase-dead mutant of PRAK (PRAK KM ), inhibited Raptor DA -induced increase of S6K1 phosphorylation (Fig. 6a) . Raptor DA -induced S6K1 phosphorylation requires Rheb (ref. 44) . Expression of Rheb enhanced S6K1 phosphorylation, and overexpression of PRAK, but not PRAK KM , inhibited Rheb-induced S6K1 phosphorylation (Fig. 6b) , indicating that PRAK is in parallel with Raptor-Rheb or directly regulates Rheb. We then found that PRAK can directly interact with Rheb, but not Raptor, as immunoprecipitation of haemagglutinin (HA)-tagged PRAK in HEK293 cells pulls down endogenous Rheb protein (Fig. 6c) . As with other kinase-substrate interactions, PRAK KM was able to more efficiently pull down Rheb when these two proteins were co-expressed ( Supplementary Fig. S4a ). An in vitro kinase assay showed that PRAK phosphorylates Rheb (Fig. 6d ), indicating that Rheb is a substrate of PRAK. To identify the phosphorylation site on Rheb, PRAK-phosphorylated Rheb was subjected to phosphopeptide mapping by mass spectrometry. Spectrum searches revealed two potential phosphorylation sites on Rheb ( Supplementary Fig. S4b ). We mutated these sites to alanine and found that only the mutation of Ser 130 abolished the phosphorylation of Rheb by PRAK ( Fig. 6d and Supplementary Fig. S4c) We then analysed whether 2-DG or AICAR induces Rheb phosphorylation and found that 2-DG and AICAR induced endogenous Rheb phosphorylation in wild-type, but not PRAK −/− , MEF cells ( Fig. 6f  and Supplementary Fig. S4f ). Overexpression of wild-type Rheb in HEK293 cells did not affect 2-DG-induced S6K1 dephosphorylation, whereas overexpression of Rheb S130A inhibited 2-DG-induced S6K1 dephosphorylation (Fig. 6g) , indicating that the S130A mutant has a dominant-negative effect on 2-DG-induced response. Consistently, overexpression of PRAK can suppress Rheb-mediated S6K1 phosphorylation, but has no effect on Rheb S130A -mediated S6K1 phosphorylation ( Supplementary Fig. S4g ). The phosphorylated form of Rheb should be less capable of inducing S6K1 phosphorylation, because the phosphomimic mutant Rheb S130E had less effect on S6K1 phosphorylation ( Supplementary Fig. S4h ). These data indicate that phosphorylation of Ser 130 on Rheb reduces its ability to activate mTORC1.
Phosphorylation of Rheb by PRAK decreases the ability of Rheb to bind guanine nucleotides
To determine why Ser 130 phosphorylation inactivates Rheb, we analysed the amount of non-hydrolysable GTP (GTP-γS) loading on recombinant Rheb or Rheb S130A in the presence of wild-type PRAK or the KM mutant of PRAK in vitro. The amount of GTP-γS that is bound to the wild-type PRAK-treated Rheb is about half of that bound to the non-phosphorylatable mutant Rheb S130A or inactive PRAK-treated sample (Fig. 7a) . As Rheb cannot hydrolyse GTP in the absence of its GAP TSC2 (ref. 30 ), a similar result was obtained when [α-32 P]GTP was used ( Supplementary Fig. S5a ). As only about half of Rheb was phosphorylated by PRAK in vitro ( Supplementary Fig. S5b ), Ser 130 phosphorylation should significantly impair GTP binding to Rheb. As we already reached our limit to increase the activity of recombinant PRAK (see Supplementary Information), we were unable to phosphorylate all Rheb in vitro, and therefore cannot obtain a precise percentage of inhibition. We also analysed the GTP-γS binding of Rheb mutants. GTP-γS loading in Rheb S130A was about the same as that in wild-type Rheb, GTP-γS loading in Rheb S130E was much less than that in wild-type, and as a negative control, PRAK protein had no GTP-γS binding (Fig. 7b) . The GDP loading was also less in Rheb S130E ( Supplementary Fig. S5c) . Thus, the phosphorylation of Ser 130 decreases guanine nucleotide binding to Rheb.
As Rheb may already bind with GTP before being phosphorylated by PRAK in cells, we loaded GTP onto Rheb first and then analysed the effect of PRAK phosphorylation of Rheb on the amount of GTP bound to Rheb. Phosphorylation of Rheb by PRAK released GTP that was bound to Rheb (Fig. 7c) . Most of the bound GTP was released within 5 min (Fig. 7d) . Thus, Ser 130 phosphorylation of Rheb not only made Rheb less capable of accepting GTP loading, but also reduced its ability to retain the already-bound GTP. To further evaluate this hypothesis, we used λ-phosphatase to remove the phosphorylation from in vitro phosphorylated Rheb and found that dephosphorylation of phospho-Rheb increased GTP binding (Fig. 7e) . To determine whether Ser 130 phosphorylation affects the GTP hydrolysis activity of Rheb, we analysed GTP hydrolysis in wild-type Rheb and Rheb S130E in the presence or absence of TSC2. As a result of the reduced GTP binding capacity by Rheb S130E , we used an excess of Rheb S130E in comparison with wild-type Rheb in the experiment (Fig. 7f, bottom right panel) . Both Rheb and Rheb S130E alone had little or no GTP hydrolysing activity, but both can hydrolyse GTP in the presence of TSC2 (Fig. 7f) . As a result of the difference in GTP binding activity, we cannot determine whether Ser 130 phosphorylation affects the hydrolysis activity of Rheb. To determine whether PRAK can regulate Rheb in cultured cells, we metabolically labelled wild-type and PRAK −/− cells with [ 32 P]phosphate. The cells were treated with or without 2-DG for 30 min, Rheb molecules were immunoprecipitated and bound nucleotides were analysed. Ras was used as a control. The ratio between GTP and GDP is about the same as in wild-type and PRAK −/− cells, and is slightly increased after 2-DG treatment in both cells (Supplementary Fig. S5d ). 2-DG reduced the ability of Rheb to bind to guanine nucleotides in wild-type cells, but not in PRAK −/− cells ( Fig. 7g and Supplementary Fig. S5e ), whereas 2-DG had no effect on the GTP binding of Ras ( Supplementary Fig. S5f ), confirming the selective regulation of Rheb by PRAK.
DISCUSSION
Previously published studies and our data described above indicate that activation of the AMPK-TSC2, AMPK-Raptor, and p38β-PRAK pathways are independent events that mediate the suppression of mTORC1. Furthermore, their activation kinetics seem to differ. For example, the activation of p38β-PRAK occurs later than the initial reduction of mTORC1 activity in energy-starved cells ( Supplementary  Fig. S1a,f) , indicating that TSC2 or Raptor suppresses mTORC1 during the early time points. It is important to note that deletion of either TSC2 or PRAK is sufficient to impair energy-depletion-induced inhibition of mTORC1 (no data for Raptor, owing to Raptor −/− cells not being available), indicating that these parallel signalling events are not simply additive. In addition, the overexpression experiments showed that any of these three genes by itself can modulate mTORC1 activity. Overactivation of one pathway can even compensate for the insufficiency of the others, as we observed that overexpression of PRAK is sufficient to suppress mTORC1 in the absence of TSC2 (Fig. 5a,b) , overexpression of TSC2 is capable of inhibiting mTORC1 regardless of the presence or absence of PRAK (Fig. 5f ) and overexpression of TSC2 in PRAK −/− cells can partially rescue the AICAR-induced decrease of S6K1 phosphorylation (Supplementary Fig. S6 ). It is possible that to inactivate mTORC1, the total activity of these pathways needs to reach a threshold. These three pathways could also operate in a network of offsetting inputs that amplify each other in inactivating mTORC1. It is clear that this is a complicated regulatory system and many other possibilities remain. mTOR receives input from multiple signalling pathways, including those that regulate growth factors, nutrients and cellular stresses. Recently, it was reported that the p38 pathway participates in the activation of mTORC1 induced by H 2 O 2 and other stimuli, and Drosophila p38b plays a role in mTORC1 activation 34 . We tested the role of p38β in H 2 O 2 -mediated changes of mTORC1. We observed suppression of mTORC1 by H 2 O 2 ( Supplementary Fig. S7a ), which is consistent with previous reports 45 . We found that p38β had no role in this response (Supplementary Fig. S7b ). On the other hand, we observed that serum starvation reduced basal levels of phospho-S6K1, and under this condition, H 2 O 2 can increase the phosphorylation of S6K1 (Supplementary Fig. S7c ), which is similar to a previous observation. We determined that H 2 O 2 -induced mTORC1 activation is not dependent on p38β (Supplementary Fig. S7d ). As Drosophila p38b is homologous to both mammalian p38α and p38β, we then analysed involvement of p38α. H 2 O 2 -induced reduction of S6K1 phosphorylation in the cells cultured in serum-containing medium was not affected by p38α deletion (Supplementary Fig. S7e ). Under serum-starved conditions, the basal level of phospho-S6K1 in p38α −/− MEF cells was higher than that in wild-type cells, and H 2 O 2 -induced increase of S6K1 phosphorylation was impaired in p38α −/− cells ( Supplementary Fig. S7f ). Thus, it is possible that p38α is responsible for the H 2 O 2 -induced mTORC1 activation previously observed 34 . Here, we demonstrate that a specific p38 kinase cascade, p38β-PRAK, is essential for energy-depletion-induced inactivation of mTORC1 (Fig. 7h) . It was not anticipated that PRAK would be able to directly regulate a component of the mTORC1 pathway. It was also surprising that the GTP binding of Rheb was able to be regulated by phosphorylation on Ser 130, as Ser 130 is located between the second 310 helix and helix IV (ref. 46 ), a region that is not within or even close to the GTP/GDP binding pocket. It is possible that Ser 130 phosphorylation changes the relative position of the second 310 helix and its flanking loops, profoundly affecting the integrity of the GTP/GDP binding pocket, and leading to a marked decrease in nucleotide binding affinity. It is also possible that Ser 130 phosphorylation affects the interaction between Rheb and its regulators. Ser 130 phosphorylation should be specific for Rheb, as this site was not found in other small GTPases (Supplementary Fig. S8a ). RhebL1 has a similar function as Rheb, but does not have a corresponding Ser 130 site 47 . We knocked down Rheb and RhebL1 in MEF cells and found that only Rheb knockdown reduced basal-level phosphorylation of S6K1 (Supplementary Fig. S8b ). This could be due to the low expression of RhebL1. As Ser 130 in Rheb is conserved from Drosophila to humans (Supplementary Fig. S8c ), the regulation of Rheb by phosphorylation could be an evolutionarily conserved mechanism for regulating mTORC1 activity. It seems that cell growth and cellular energy levels need to be precisely coordinated, and cells have evolved multiple checkpoints to regulate Rheb activity.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology/
Note: Supplementary Information is available on the Nature Cell Biology website

METHODS
Reagents and antibodies. Anti-Rheb (344912; 1:500) was from R&D Systems. Mouse anti-PRAK (A-7; 1:1,000) and anti-Rheb (C-19; 1:500) were from Santa Cruz Biotechnology. Anti-Ras (Y13-259; 1:1,000) was from Transduction Laboratories. Rabbit anti-PRAK antibodies were raised using recombinant PRAK. Anti-phospho-PRAK (T182; 1:1,000) was generated with phospho-peptide 48 . Anti-phospho-Rheb (S130) (1:200) was generated by Abmart. All other antibodies (1:1,000) were from Cell Signaling. 2-DG was obtained from Sigma. AICAR (AICA-Riboside) and rapamycin were obtained from Calbiochem. Phos-tag was obtained from Phos-tag Technology. The expression plasmids of human p38β (Flag-p38β) and PRAK (histidine (His)-tagged PRAK, HA-PRAK and Flag-PRAK) were described previously 49 . The expression plasmids of human S6K (HA-S6K and Flag-S6K) and Rheb (Myc-Rheb) were described previously 50 . To generate His or glutathione S-transferase (GST) fusion of Rheb, Rheb was expressed in pET or pGEX vectors. The lentiviral vectors from Invitrogen were used to express protein and shRNA in cultured cells. All mutant constructs of Rheb and PRAK were created by PCR mutagenesis and were verified by DNA sequencing. The real-time PCR primers were as follows: Rheb, forward, 5 -TGGCAAATTGTTGGATATGG-3 , reverse, 5 -CCAAAGCTTTCCCTTCTTCA-3 ; RhebL1, forward, 5 -AAGAAGCTGGCAGAGTCCTG-3 , reverse, 5 -CAATCTCCTGGA-TGACTTTGG-3 ; p38α, forward, 5 -TTGGTCAGTGGGATGCATAA-3 , reverse, 5 -AGTTTCTTGCCTCATGGCTT-3 ; p38γ, forward, 5 -GTCATCT-TGAATTGGATGCG-3 , reverse, 5 -TGTAGTTCTTGGCCTCATCG-3 ; p38δ, forward, 5 -CCAGACAGTGGACATCTGGT-3 , reverse, 5 -CTTTGTCGTTCAGCTTCTGC-3 ; MK2, forward, 5 -GGTCCCTGGGT-GTCATCATGT-3 reverse, 5 -GCCAGTATGAATTTCCCAACC-3 ; p38β, forward, 5 -GCCATATGATGAGAGCGTTG-3 reverse, 5 -GTGAGCT-CCTTCCACTCCTC-3 .
Cell culture, transfection and lentivirus infection. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) containing 10% fetal bovine serum (FBS; Invitrogen). Calcium phosphate precipitation or Lipofectamine 2000 was used for cell transfection. HEK293FT was used to prepare the lentivirus, as described in ViraPower Lentiviral Expression System (Invitrogen).
MEFs. Embryonic fibroblasts obtained from p38α lox/lox
, p38β lox/lox ,p38γ lox/lox and p38δ lox/lox mice were cultured in DMEM supplemented with 10% FBS. MEFs were immortalized with a retrovirus expressing large T antigen. To generate gene-knockout MEF cells, the p38α lox/lox , p38β lox/lox ,p38γ lox/lox and p38δ lox/lox MEF cells were infected with a retrovirus expressing Cre to excise the floxed gene. Cells infected with an empty retrovirus vector were also generated and used as control wild-type cells. The gene knockout was confirmed by genomic PCR. The PRAK −/− cell line was generated by immortalizing primary MEF cells with a retrovirus expressing large T antigen. TSC2 −/− MEF cells were described previously 51 . AMPK α1/α2 −/− cells were obtained from B. Viollet (Universite Paris Descartes) and K. R. Laderoute (Stanford University School of Medicine).
RNA interference. shRNAs were designed using Invitrogen Block-iT RNAi Designer and cloned into a lentiviral vector from Invitrogen. We designed several shRNAs to target human PRAK, MK2, p38β and Rheb, and found the following sequence to be able to effectively knock down the target genes:
GFP shRNA, 5 -GGCACAAGCTGGAGTACAA-3 ; PRAK shRNA 1, 5 -GCAAGCCAGCCAAGTAACA-3 ; PRAK shRNA 2, 5 -GCAGGAGGCT-TGGAAGTAT-3 ; MK2 shRNA 1, 5 -GGAGAACTCTTTAGCCGAATC-3 ; MK2 shRNA 2, 5 -GGTCCCTGGGTGTCATCATGT-3 ; p38β shRNA 1, 5 -CTCAGAACACGCCCGGACA-3 ; p38β shRNA 2, 5 -GCTGAAGCGCATCATGGAA-3 .
Lentiviruses were collected 48 h after transfection of HEK293FT cells with lentiviral vectors. The shRNA-expressing lentiviruses were used to infect HEK293 cells. The cells were analysed 3 days after infection. p38α, p38γ and p38δ shRNAs were as previously described 52 .
Immunoprecipitation. Cells were lysed in lysis buffer (20 mM Tris at pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na 3 VO 4 and 1 µg ml −1 leupeptin) and immunoprecipitated with anti-HA or anti-Flag antibody-conjugated protein A/G-Sepharose beads. Immunocomplexes were subjected to SDS-PAGE.
Cell-size assay. Cell-size determination was described previously 3 . Briefly, FACS analysis was carried out on Coulter Epics XL, Beckman. Cells were replated to a 10 cm dish (1:10 split). After 12 h, the cells were treated as indicated. The cultured medium was changed every 24 h. The cells were then collected and fixed on ice in 75% ethanol, then stored at 4 • C until analysis. The fixed cells were treated with 250 µg ml −1 RNase A and stained with propidium iodide for FACS analysis, to determine the cell size in the G1-phase population.
In vitro kinase assay. GST-PRAK, His-p38β, His-MKK6b E , GST-Rheb, His-PRAK and His-Rheb were purified from Escherichia coli and subjected to a kinase assay in kinase buffer (25 mM Tris at pH 7.5, 10 mM MgCl 2 , 2 mM dithiothreitol, 5 mM β-glycerophosphate and 0.1 mM Na 3 VO 4 ) at 30 • C for 30 min. To generate activated PRAK, GST-PRAK was subjected to a kinase assay using His-p38β and His-MKK6b E as kinases. GST-PRAK was then repurified using GST beads. To generate phosphorylated Rheb, GST-Rheb was subjected to a kinase assay using activated PRAK as a kinase.
GTP loading assay. GST-Rheb and phosphorylated Rheb, GST-Rheb S130A or GST-Rheb S130E were loaded with [α-32 P]GTP in loading buffer (20 mM Tris at pH 8, 5 mM EDTA, 1 mM dithiothreitol and 0.1 mg ml −1 BSA) for 15 min at 30 • C (ref. 53 ). This mixture was applied to a nitrocellulose membrane (Bio-Rad), then rinsed three times with Tris-buffered saline (20 mM Tris at pH 7.6 and 137 mM NaCl). The radioactivity retained on the membrane was determined by scintillation counting.
Mn 2+ -phos-tag SDS-PAGE. Electrophoresis of the polyacrylamide gel containing Mn 2+ -phos-tag was conducted as described previously 54 , except a 15% polyacrylamide gel was used.
Mass spectra and phosphorylation site mapping. Recombinant Rheb was phosphorylated in vitro by active PRAK. The phosphorylated Rheb was resuspended in 8 M urea, 100 mM Tris at pH 8.5, reduced, alkylated, split into three tubes, and digested with trypsin, elastase and thermolysin. The three digests were pooled together for mass spectrometry analysis. The tandem mass spectrograms were searched with SEQUEST (ref. 55) , with or without the addition of 80 on serine, threonine or tyrosine (phosphorylation) against a human protein database. The MS3 spectra were searched with SEQUEST with a loss of 18 on serine or threonine (neutral loss of phosphoric acid from phosphorylated serine or threonine). The search results were combined and filtered with DTASelect (ref.
56).
Isoelectric focusing and immunoblotting. Proteins were precipitated with trichloroacetic acid 3-[(3-Cholamidopropyl)-dimethylammonio]-1-propanesulfonate (TCA)/acetone, suspended in IEF sample buffer (7 M urea, 2 M thiourea, 2% CHAPS, 0.8% ampholytes at pH 3-10, 50 mM dithiothreitol and 4% glycerol) and applied to isoelectric focusing using a mini-gel format as described previously 57 . After focusing, IEF gels were incubated in 12% TCA overnight at 4 • C, washed three times with water for 15 min, incubated in 7 M urea, 2 M thiourea and 5 mM dithiothreitol for 10 min to renature the proteins, then soaked in lower gel buffer (0.37 mM Tris at pH 8.8 and 0.1% SDS) three times for 15 min. The focused proteins were then transferred onto a 0.45 µm poly(vinylidene fluoride) membrane and immunoblotted with anti-phospho-Rheb and anti-Rheb antibodies.
Metabolism labelling. PRAK +/+ and PRAK −/− MEF cells were washed once with phosphate-free DMEM and incubated with phosphate-free DMEM containing 0.5 mCi/ml 32 P-orthophosphate for 4 h. Cells were treated without or with 25 mM 2-DG for 30 min. The cells were lysed with labelling lysis buffer (1% Triton X-100, 50 mM HEPES at pH 7.4, 100 mM NaCl, 5 mM MgCl 2 , 1 mg ml −1 BSA, 1 mM dithiothreitol, 1 mM phenylmethyl sulphonyl fluoride, 10 µg ml −1 leupeptin, 10 µg ml −1 aprotinin, 1 mM NaVO 3 and, 10 mM NaF). Rheb and H-Ras were immunoprecipitated with 20 µl anti-Rheb (C-19) and 10 µl anti-H-Ras (Y13-259) antibodies, respectively 58, 59 . Protein A/G beads were added for 1 h at 4 • C. The beads were washed eight times with a washing buffer (0.5% Triton X-100, 50 mM HEPES at pH 7.4, 5 mM MgCl 2 , 1 mM NaVO 3 , 0.005% SDS). The bound nucleotides were eluted with 20 µl elution buffer (2 mM EDTA at pH 8.0, 1 mM GDP, 1 mM GTP) at 68 • C for 20 min. SDS-sample buffer was added to beads for analysing the protein in the immuoprecipitates. Methanol (60 µl) and chloroform (30 µl) were added to the eluates, each followed by vortexing and centrifugation at 11,750 g for 10 s. Water (45 µl) was added and the samples were centrifuged again at 11,750 g for 2 min. The upper phase was collected and dried, then resuspended in 15 µl elution buffer. The eluted nucleotides were subjected to thin-layer chromatography using polyethyleneimine cellulose plates (Baker-flex) in 0.75 M KH 2 PO 4 (pH 3.4). Data were collected with a Phosphorimager (Molecular Dynamics) and analysed with the ImageQuant program.
Statistics. Data are expressed as means ± s.e.m. Student's t -test was used to compare differences between treated groups and their paired controls. P values are indicated in the figures. Figure S1 (a) p38β +/+ and p38β -/-MEF cells were treated with 25 mM 2-DG for different periods of time. Phosphorylation of S6K1, S6K1 protein levels, and β-actin protein levels were determined by Western blotting using antiphospho-S6K1, anti-S6K1, and anti-β-actin antibodies, respectively. (b) HEK293 cells were infected with retroviruses expressing control, p38β-sh1, p38β-sh2, p38α-sh1, p38α-sh2, p38γ-sh1, p38γ-sh2, p38δ-sh1, and p38δ-sh2. 48 hours later, cells were treated with 2-DG for 0, 15, 30, and 60 minutes. Phosphorylation of S6K1 and S6K1 protein levels were determined as described in a. Relative mRNA levels of each p38 isoform were measured by real-time PCR. Data are represented as mean +/-s.e.m., n=3 samples. (c) HEK293 cells were transfected with HA-S6K1 and Flag-p38α, Flagp38β, Flag-p38γ, or Flag-p38δ, respectively. Phosphorylation of S6K1 and S6K1 protein levels were determined as described in a. Protein levels of p38 isoforms were detected by anti-Flag antibodies. (d) HEK293 cells were transfected with HA-S6K1 and Flag-p38α, Flag-p38β, Flag-p38γ, or Flagp38δ, respectively. Cells were treated with 25 mM 2-DG. Phosphorylation and protein levels of p38 isoforms were detected by anti-phospho-p38 and anti-Flag antibodies, respectively. and Flag-p38α, Flag-p38β, Flag-p38γ, or Flag-p38δ, respectively. Phosphorylation of S6K1 and S6K1 protein anti-phospho-S6K1, anti-S6K1, and anti-β-actin antibodies, respectively. (b) HEK293 cells were infected with retroviruses expressing control, p38β-sh1, p38β-sh2, p38α-sh1, p38α-sh2, p38γ-sh1, p38γ-sh2, p38δ-sh1, and p38δ-sh2. 48 hours later, cells were treated with 2-DG for 0, 15, 30, and 60 minutes. Phosphorylation of S6K1 and S6K1 protein levels were determined as described in a. Relative mRNA levels of each p38 isoform were measured by reallevels were determined as described in a. Protein levels of p38 isoforms were detected by anti-Flag antibodies. (d) HEK293 cells were transfected with HA-S6K1 and Flagp38α, Flag-p38β, Flag-p38γ, or Flag-p38δ, respectively. Cells were treated with 25 mM 2-DG. Phosphorylation and protein levels of p38 isoforms were detected by antiphospho-p38 and anti-Flag antibodies, respectively. Phosphorylation of S6K1 and S6 were determined by Western blotting using anti-phospho-S6K1 and anti-phospho-S6 antibodies, respectively. β-actin and S6K1 protein levels were determined by Western blotting using anti-β-actin and anti-S6K1 antibodies. Relative mRNA levels of MK2 were measured by real-time PCR 60 hours after infection (right panel). S6 were determined by Western blotting using antiphospho-S6K1 and anti-phospho-S6 antibodies, respectively. β-actin and S6K1 protein levels were determined by Western blotting using anti-β-actin and anti-15, 30, or 60 minutes. Phosphorylation of S6K1, S6K1 protein levels, and PRAK protein levels were determined by Western blotting using anti-phospho-S6K1, anti-S6K1 or anti-PRAK antibodies, respectively. protein levels of S6K1 were determined by Western blotting as described in a. β-actin protein levels were determined by Western blotting using anti-β-actin antibodies. (c) His-Rheb, His-Rheb-T44A, or His-Rheb-S130A were applied to an in vitro kinase assay using PRAK as its kinase. Phosphorylation of Rheb was detected by autoradiography. Rheb and PRAK protein levels were determined by Coomassie blue staining. (d) HEK293 cells were infected with increasing amounts of PRAK-expressing lentiviruses. Phosphorylation of Rheb, S6K1, and S6 were determined by Western blotting using anti-phospho-Rheb, antiphospho-S6K1, and anti-phospho-S6 antibodies, respectively. Protein levels of S6K1, S6, Rheb, and PRAK were determined by Western blotting using anti-S6K1, anti-S6, anti-Rheb and anti-PRAK antibodies, respectively. (e)
The expression vector of Myc-Rheb and its mutants (WT: wildtype, A: S130A, AA: S130A/T44A) were co-transfected with PRAK or PRAK(KM) into HEK293 cells as indicated. Phos-Tag SDS-PAGE was applied to detect the band shift of Rheb caused by phosphorylation. Myc-Rheb and PRAK were determined by Western blotting with anti-Myc and anti-PRAK antibodies, respectively. The same samples were also analyzed by Western blotting of standard SDS-gel with anti-phospho-Rheb antibodies (top panel). (f) PRAK +/+ and PRAK -/-MEF cells were treated with 0.5 mM AICAR for 0, 2, or 4 hours. Phoshorylation of Rheb and Rheb protein levels were determined by Western blotting using antiphospho-Rheb and anti-Rheb antibodies, respectively. (g) PRAK suppresses the function of Rheb, but not Rheb-S130A or Rheb-S130E. Plasmids were co-transfected into HEK293 cells as indicated. 18 hours post-transfection, cells were harvested. Phosphorylation of S6K1, HA-S6K1 protein levels, Myc-Rheb protein levels, PRAK protien levels, and Flag-p38β protein levels were determined by Western blotting. (h) Mutation of serine 130 to glutamic acid (E) decreases Rheb activity. HA-S6K1 was co-transfected with an empty vector, Myc-Rheb, Myc-Rheb-S130A, or Myc-Rheb-S130E into HEK293 cells. Cells were harvested 18 hours post transfection. The levels of phosphor-S6K1, HA-S6K1, and Myc-Rheb were determined by Western blotting. 
